Figure 3: Smad3-dependent tumour microenvironment is derived from the bone marrow.
From: Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development
LLC-luc or B16F10-luc cancer cells were s.c. inoculated into GFP+ Smad3+/+ and GFP+ Smad3−/− chimeric mice and examined for: (a) bone marrow-derived NK cells (GFP+ NK1.1+) in the tumour tissues by two-colour immunofluorescence; (b,c) tumour growth patterns by bioluminescent imaging, tumour volumes, tumour weights on day 21 and the survival rate of LLC (b) or B16F10 (c) tumour-bearing chimeric mice. Data represent mean±s.d. for groups of 4–5 mice. *P<0.05, **P<0.01 compared with tumour-bearing Smad3+/+ chimeric mice received GFP+ Smad3−/− bone marrow transplantation analysed by analysis of variance. Scale bars, 100 μm.
